Targeting CCR2+ macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting CCR2+ macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer
Authors
Keywords
-
Journal
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-01-30
DOI
10.1007/s00432-021-03885-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Achieving clinical success with BET inhibitors as anti-cancer agents
- (2021) Tatiana Shorstova et al. BRITISH JOURNAL OF CANCER
- Activating a collaborative innate-adaptive immune response to control metastasis
- (2021) Lijuan Sun et al. CANCER CELL
- Infiltration by CXCL10 Secreting Macrophages Is Associated With Antitumor Immunity and Response to Therapy in Ovarian Cancer Subtypes
- (2021) Laura Ardighieri et al. Frontiers in Immunology
- CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis
- (2020) Hui Yang et al. Molecular Cancer
- Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses
- (2020) Jesse M. Jaynes et al. Science Translational Medicine
- TIMER2.0 for analysis of tumor-infiltrating immune cells
- (2020) Taiwen Li et al. NUCLEIC ACIDS RESEARCH
- Role of M1-polarized tumor-associated macrophages in the prognosis of advanced ovarian cancer patients
- (2020) Antonio Macciò et al. Scientific Reports
- Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology
- (2019) Gregor Sturm et al. BIOINFORMATICS
- Ovarian Cancer Immunotherapy: Turning up the Heat
- (2019) Eleonora Ghisoni et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer
- (2019) Krishnansu S. Tewari et al. JOURNAL OF CLINICAL ONCOLOGY
- PSMP/MSMP promotes hepatic fibrosis through CCR2 and represents a novel therapeutic target
- (2019) Shaoping She et al. JOURNAL OF HEPATOLOGY
- Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: Correlation with blood monocyte counts.
- (2018) David Linehan et al. JOURNAL OF CLINICAL ONCOLOGY
- Paclitaxel reduces tumor growth by reprogramming tumor-associated macrophages to an M1- profile in a TLR4-dependent manner
- (2018) Carlos W Wanderley et al. CANCER RESEARCH
- Impact of Genetic Polymorphisms on Human Immune Cell Gene Expression
- (2018) Benjamin J. Schmiedel et al. CELL
- Predicting novel therapies and targets: Regulation of Notch3 by the bromodomain protein BRD4
- (2018) Alejandro Villar-Prados et al. MOLECULAR CANCER THERAPEUTICS
- Targeting macrophages: therapeutic approaches in cancer
- (2018) Luca Cassetta et al. NATURE REVIEWS DRUG DISCOVERY
- Tumor-associated macrophages: implications in cancer immunotherapy
- (2017) Amy J Petty et al. Immunotherapy
- Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
- (2017) Robert L Coleman et al. LANCET ONCOLOGY
- Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP)
- (2017) T Mitamura et al. ONCOGENE
- Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy
- (2017) B A Castro et al. ONCOGENE
- Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas
- (2017) D Yan et al. ONCOGENE
- BET Proteins as Targets for Anticancer Treatment
- (2017) Anastasios Stathis et al. Cancer Discovery
- Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy
- (2017) Yasmin A. Lyons et al. Oncotarget
- Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer
- (2016) Mingzhu Yin et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
- (2016) Timothy M Nywening et al. LANCET ONCOLOGY
- Ten years of anti-vascular endothelial growth factor therapy
- (2016) Napoleone Ferrara et al. NATURE REVIEWS DRUG DISCOVERY
- Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma
- (2015) Xiaoguang Li et al. GUT
- Robust enumeration of cell subsets from tissue expression profiles
- (2015) Aaron M Newman et al. NATURE METHODS
- Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy
- (2014) Carola H. Ries et al. CANCER CELL
- CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models
- (2014) Y. Zhu et al. CANCER RESEARCH
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- (2014) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- PC3-Secreted Microprotein Is a Novel Chemoattractant Protein and Functions as a High-Affinity Ligand for CC Chemokine Receptor 2
- (2014) X. Pei et al. JOURNAL OF IMMUNOLOGY
- CSF-1R inhibition alters macrophage polarization and blocks glioma progression
- (2013) Stephanie M Pyonteck et al. NATURE MEDICINE
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- (2012) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
- (2011) Bin-Zhi Qian et al. NATURE
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More